Lutropin alfa
Registry-listed formulations
Lutropin alfa · chembl:CHEMBL1201419
Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.
2 source entries across 1 studies. This list may not include all unresolved or historical entries.
- Luveris 75 IU powder and solvent for solution for injectionRegistry product
Molecular identity unconfirmed
Formulation reported by source: SOLUTION FOR INJECTION
Named ingredient; exact form unconfirmed. This mention does not add to the molecule trial count.
View study and source - Luveris 75 IU powder and solvent for solution for injectionRegistry product
Molecular identity unconfirmed
Formulation reported by source: SOLUTION FOR INJECTION
Named ingredient; exact form unconfirmed. This mention does not add to the molecule trial count.
View study and source
Success Metrics
Phase Distribution
Phase Distribution
0
Early Stage
1
Mid Stage
2
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
0.0%
0 of 1 finished
100.0%
1 ended early
0
trials recruiting
3
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Effect of LH Supplementation on the Endometrial Gene Expression Profile in Poor Ovarian Responders
Rec-LH PD and Safety Profile in Hypogonadotropic Hypogonadism Men
Comparison of Assisted Reproductive Technology (ART) Outcomes Between Two Protocols of Induction of Ovulation in Patients With Hypogonadotropic Hypogonadism
Clinical Trials (3)
Effect of LH Supplementation on the Endometrial Gene Expression Profile in Poor Ovarian Responders
Rec-LH PD and Safety Profile in Hypogonadotropic Hypogonadism Men
Comparison of Assisted Reproductive Technology (ART) Outcomes Between Two Protocols of Induction of Ovulation in Patients With Hypogonadotropic Hypogonadism
All 3 trials loaded
Drug Details
- Intervention Type
- Drug
- Molecule Type
- Protein
- Total Trials
- 3